NCT03742154

Hollings Cancer Center Varenicline Sampling Study

A Pilot Translational Study of Varenicline Sampling to Promote Treatment Engagement and Smoking Cessation

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 99 (actual)
• Sponsor: Medical University of South Carolina · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to learn what happens when people are given a free, 4-week, sample of varenicline, a smoking cessation medication. Investigators will look at quit attempts, changes in smoking, and attitude towards varenicline, in both smokers who want to quit and those who do not. Smoking use causes a number of deaths and diseases, including heart disease and cancer. All smokers are advised to quit. Varenicline (sometimes called Chantix), is a prescription medication approved by the US FDA. Many studies show that use of varenicline can help smokers quit smoking. Varenicline is a prescription medication, which usually means that people have to see a doctor to get it. This study examines a different way to deliver varenicline, delivered directly to participants for a few weeks, and without need to see a doctor. This method is called "varenicline sampling." The study is sponsored by the Hollings Cancer Center at the Medical University of South Carolina. The study is being done at the Medical University of South Carolina, but study recruitment is based state-wide, throughout South Carolina.

Conditions

• Smoking
• Smoking Cessation
• Smoking, Tobacco
• Smoking, Cigarette

Interventions

Type	Name	Description
DRUG	Varenicline 0.5 MG	varenicline comes in bottles of 56 - 0.5 mg pills

Timeline

• Start date: 2018-12-03
• Primary completion: 2020-04-06
• Completion: 2020-04-06
• First posted: 2018-11-15
• Last updated: 2020-10-28
• Results posted: 2020-10-09

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study